13F Holdings
中文EN

STLN Starling Oncology, Inc.

Services-Offices & Clinics of Doctors of Medicine · Nasdaq · SEC CIK 1799191 · Fiscal year ends 12/31

Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY21.7%
TTM net income YoY5.6%
TTM EPS YoY16.9%
Revenue 3-yr CAGR25.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-8.9%
Net margin-14.4%
FCF margin-6.0%
EBITDA margin-7.4%

Returns

ROE-4,132.2%
ROA-38.7%
ROIC (approx.)-67.7%
Asset turnover2.69x

Leverage & solvency

Liabilities / assets107.5%
Debt / equity—
Current ratio1.68x
Interest coverage-3.90x

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-24.8%
Payout ratio—
Capex / revenue0.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$502.73M$393.41M$324.24M$252.48M$203.00M
SG&A expense$105.57M$107.83M$113.85M$119.69M$83.36M
Operating income-$36.08M-$60.12M-$77.02M-$81.95M-$45.86M
Interest expense$11.28M$7.50M$6.78M—$320,000
Pretax income-$60.74M-$64.66M-$83.10M-$91,000-$11.60M
Income tax-$131,000$0-$36,000-$243,000-$671,000
Net income-$60.61M-$64.66M-$83.07M$152,000-$10.93M
EBITDA-$29.14M-$53.83M-$71.14M-$77.54M-$42.52M
EPS (basic)-0.54-0.71-0.920.00-0.16
EPS (diluted)-0.54-0.71-0.92-0.21-0.16
Weighted avg. shares (diluted)92.39M75.04M73.75M80.61M66.23M
Banking
Net interest income——-$6.78M-$4.08M-$320,000
Balance sheet
Cash & equivalents$33.56M$49.67M$33.49M$14.01M$115.17M
Short-term investments—$0$49.37M$59.80M$0
Receivables$59.00M$48.34M$42.36M$39.82M$20.01M
Inventory$16.88M$10.04M$13.68M$9.26M$6.44M
Current assets$112.75M$112.42M$143.49M$130.42M$154.06M
PP&E, net$10.68M$11.89M$10.88M$8.55M$4.19M
Goodwill$7.23M$7.23M$7.23M$21.42M$26.63M
Intangibles$11.02M$14.81M$17.90M$17.96M$18.25M
Total assets$164.66M$172.72M$209.24M$261.67M$203.44M
Current liabilities$70.96M$52.22M$34.79M$29.72M$29.80M
Short-term debt———$0$183,000
Long-term debt$77.40M$93.13M$86.83M$80.62M$0
Total debt$77.40M$93.13M$86.83M$80.62M$183,000
Total liabilities$180.38M$169.13M$152.22M$138.49M$99.28M
Shareholders' equity-$15.72M$3.59M$57.02M$123.17M$104.16M
Net debt$43.84M$43.46M$53.34M$66.61M-$114.99M
Shares outstanding98.86M75.74M74.15M73.27M73.25M
Cash flow statement
Operating cash flow-$24.59M-$26.54M-$36.31M-$61.76M-$32.68M
Capital expenditure$3.20M$3.79M$4.57M$5.53M$2.85M
Free cash flow-$27.79M-$30.33M-$40.88M-$67.28M-$35.53M
Investing cash flow-$3.07M$46.21M$62.64M-$131.61M-$12.15M
Financing cash flow$11.56M-$3.49M-$6.85M$92.21M$154.01M
Depreciation & amortization$6.94M$6.29M$5.87M$4.41M$3.34M
Stock-based compensation$4.55M$11.15M$17.81M$27.68M$24.54M
Share buybacks—$0$1.02M$9.00M$0

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.